While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.
Learn from academia and industry experts about clinical epigenetics, discussing solutions to challenges like drug discovery, identification of molecular inhibitors, gene modification and analysis.
Our expert speaker panel will address emergence of novel drugs and next-generation diagnostic technologies with respect to huge growth, government funding for epigenetics research. The congress will host effective mix of case studies, panel discussion and presentations on development of epigenetics, translational epigenetics, clinical epigenetics and more.
Engage with pioneers and leaders from academia and industry and stay updated with the latest advancement in epigenetics research right from drug discovery to identification of molecular inhibitors to gene modifications and analysis.
Epigenetic modification | Genomic profiling | Transcriptional mechanism | Molecular inhibitors | Epigenetic modulators | Clinical applications of epigenetics
Heads, Directors, Group Leaders, Professors, Lecturers, Research Associates, Scientists, Investigators, Fellows, Readers from Pharmaceutical, Bio-pharmaceutical and Research Institutes
Epigenetics | Developmental Epigenetics | Epidemiology | Molecular Biology | Developmental Biology | Biological Sciences | Biochemistry | Medicinal Chemistry | Pharmaceutical chemistry
Radisson Blu Edwardian Hotels is a collection of luxury hotels in central London, Heathrow and Manchester. The Edwardian experience is about a new kind of luxury which makes you feel immediately comfortable and never intimidated.
For any queries regarding the hotel booking please write to us at [email protected]
Hotel Booking Link
You will receive a link to book your accommodation via email once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on [email protected]
About five months ago Passage Bio that basically produces gene therapies for not so common monogenic CNS disease, in partnership with Catalent's paragon launched a unit that is devoted to manufacturing suite Paragon Harman's, MD, facility. The other cGMP suite whose worth is not being revealed yet is expected to hit it's functional phase from mid-2020 and is support Passage Bio's supply requirements from clinical through commercial phases. Read more....
Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). Read more...
A new treatment for a rare childhood disorder which cost $2.125 million for a single dose, one of the most expensive medicine available is approved by The US Food and Drug Administration. Read more....